Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Paclitaxel by Fulgent Pharma for Hypopharyngeal Cancer: Likelihood of Approval
Paclitaxel is under clinical development by Fulgent Pharma and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase...
Paclitaxel by Fulgent Pharma for Laryngeal Cancer: Likelihood of Approval
Paclitaxel is under clinical development by Fulgent Pharma and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase...
Paclitaxel by Fulgent Pharma for Nasopharyngeal Cancer: Likelihood of Approval
Paclitaxel is under clinical development by Fulgent Pharma and currently in Phase II for Nasopharyngeal Cancer. According to GlobalData, Phase...
Paclitaxel by Fulgent Pharma for Oropharyngeal Cancer: Likelihood of Approval
Paclitaxel is under clinical development by Fulgent Pharma and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase...
Paclitaxel by Fulgent Pharma for Paranasal Sinus And Nasal Cavity Cancer: Likelihood of Approval
Paclitaxel is under clinical development by Fulgent Pharma and currently in Phase II for Paranasal Sinus And Nasal Cavity Cancer....
Paclitaxel by Fulgent Pharma for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Paclitaxel is under clinical development by Fulgent Pharma and currently in Phase II for Oral Cavity (Mouth) Cancer. According to...
Paclitaxel by Fulgent Pharma for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Paclitaxel is under clinical development by Fulgent Pharma and currently in Phase II for Recurrent Head And Neck Squamous Cell...
Paclitaxel by Fulgent Pharma for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Paclitaxel is under clinical development by Fulgent Pharma and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...